Nektar Therapeutics Quarterly Balance Sheet
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nektar Therapeutics financial position
As of Jun 30, 2026, Nektar Therapeutics reported total assets of $1.10 billion, up 427.7% from a year earlier against total liabilities of $192.0 million. Shareholders' equity stood at $903.1 million, or 82.5% of assets. The company held $39.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.42, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Nektar Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 39.27M | 149.58M | 15.12M | 41.03M | 42.99M | 38.89M | 44.25M | 30.11M | 27.94M | 48.64M | 35.28M | 64.92M |
| Short-Term Investments | 645.07M | 419.03M | 230.64M | 229.18M | 132.91M | 179.74M | 210.97M | 214.39M | 243.29M | 240.60M | 268.34M | 307.74M |
| Receivables | — | — | — | — | — | — | 0 | 0 | 1.20M | 3.62M | 1.21M | 2.20M |
| Inventory | — | — | 0 | — | — | — | 0 | 0 | 14.46M | 16.24M | 16.10M | 15.13M |
| Total Current Assets | 739.40M | 589.04M | 266.27M | 281.36M | 186.57M | 229.91M | 261.29M | 286.48M | 295.19M | 319.84M | 330.70M | 399.02M |
| Property, Plant & Equipment | — | — | 2.06M | 2.83M | 2.99M | 3.16M | 3.41M | 3.60M | 15.19M | 17.48M | 18.86M | 19.95M |
| Goodwill | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Long-Term Investments | 339.06M | 162.99M | 0 | 0 | 0 | 2.02M | 13.87M | 4.54M | 19.41M | 36.78M | 25.82M | — |
| Total Assets | 1.10B | 763.27M | 280.41M | 301.35M | 207.53M | 256.24M | 303.85M | 307.97M | 343.33M | 396.01M | 398.03M | 442.24M |
| Accounts Payable | 24.89M | 10.03M | 10.77M | 15.56M | 14.28M | 17.83M | 11.56M | 8.58M | 6.47M | 8.76M | 9.85M | 3.29M |
| Total Current Liabilities | 70.98M | 57.71M | 53.54M | 66.34M | 71.39M | 70.93M | 61.40M | 67.58M | 57.33M | 52.41M | 51.27M | 52.11M |
| Total Liabilities | 192.01M | 187.06M | 190.57M | 216.26M | 231.75M | 242.50M | 243.11M | 259.08M | 263.65M | 269.31M | 267.05M | 282.88M |
| Shareholders' Equity | 903.12M | 576.22M | 89.83M | 85.09M | -24.21M | 13.74M | 60.74M | 48.88M | 79.69M | 126.70M | 130.99M | 159.37M |
| Retained Earnings | -3.85B | -3.81B | -3.76B | -3.72B | -3.69B | -3.65B | -3.60B | -3.60B | -3.57B | -3.51B | -3.48B | -3.44B |
| Net Cash (Debt) | 684.34M | 568.60M | 245.75M | 270.21M | 175.90M | 218.63M | 255.23M | 244.50M | 271.24M | 289.24M | 303.62M | 372.66M |
| Shares Outstanding | 20.38M | 20.38M | 20.38M | 19.65M | 12.46M | 186.10M | 12.39M | 184.46M | 184.06M | 183.62M | 191.38M | 190.77M |
This table shows 12 quarterly periods of Nektar Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NKTR's reporting calendar. What is a balance sheet?